Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00846560
Recruitment Status : Withdrawn (Changes in the lab's focus and needs)
First Posted : February 18, 2009
Last Update Posted : October 11, 2017
Sponsor:
Information provided by (Responsible Party):
d_yarnitsky, Rambam Health Care Campus

Tracking Information
First Submitted Date February 15, 2009
First Posted Date February 18, 2009
Last Update Posted Date October 11, 2017
Actual Study Start Date August 2008
Actual Primary Completion Date July 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures Not Provided
Original Primary Outcome Measures Not Provided
Change History Complete list of historical versions of study NCT00846560 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)
Official Title Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)
Brief Summary The involvement of Lymphocyte type B in Amyotrophic lateral sclerosis (ALS) patients will be compared to lymphocyte in healthy subjects.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Other
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Amyotrophic lateral sclerosis and Healthy subjects
Condition Amyotrophic Lateral Sclerosis
Intervention Not Provided
Study Groups/Cohorts
  • 1 ALS patients
  • 2 Healthy subjects
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Withdrawn
Actual Enrollment
 (submitted: October 10, 2017)
0
Original Estimated Enrollment
 (submitted: February 17, 2009)
20
Actual Study Completion Date July 2009
Actual Primary Completion Date July 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • ALS patients who could sign ICF.

Exclusion Criteria:

  • No ALS patients age less than 18 years.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 100 Years   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Israel
Removed Location Countries  
 
Administrative Information
NCT Number NCT00846560
Other Study ID Numbers ALS04CTIL
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party d_yarnitsky, Rambam Health Care Campus
Study Sponsor Rambam Health Care Campus
Collaborators Not Provided
Investigators Not Provided
PRS Account Rambam Health Care Campus
Verification Date October 2017